chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during breast feeding, Maternal exposure during pregnancy, Pregnancy test
Clinical narrative: Maternal exposure during breast feeding; Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) and MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) in a 38-year-old female patient (gravida 1, para 0) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031l20a and 012l20a) for COVID-19 vaccination.     The patient's past medical history included Alcoholic. Family history included Hirschsprung's disease (Patient's brother had Hirschsprung's disease history was reported.). Concurrent medical conditions included Sulfonamide allergy and Hypothyroidism since 17-Dec-2020. Concomitant products included LEVOTHYROXINE from 17-Dec-2020 to an unknown date for Hypothyroidism.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 27-Aug-2020 and the estimated date of delivery was 22-May-2021. On 08-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). On an unknown date, the patient experienced MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-ninth week of the pregnancy. The vaginal delivery occurred on 24-May-2021, which was reported as Full-term. For neonate 1, the birth weight was 3350 grams (7lbs 6oz) with an APGAR score of 8 and 9 at (1, 5 minutes). The outcome was reported as Delivered NOS. fetus height 53.34 cm and 39 weeks of gestation was reported. On 08-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved. At the time of the report, MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Oct-2020, Pregnancy test: Positive.         Concomitant product used included prenatal gummy medications which is taking orally from 01 Oct 2020 for pregnancy.Fetus detail includes identified infant abnormalities at 1 month post-partum  laryngeal malacia was reported.Pregnancy related complications included hypothyroidism. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Significant Follow-up contains pregnancy information,allergy,Pregnancy test,LMP date,height and weight race of the patient,fetus details, family history and best doctor information and concomitant products.
Age: 16.0
Sex: U
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: 16 year old; A spontaneous report was received from a Pharmacist concerning a 16 years old patient of unspecified gender who received Moderna's COVID-19 vaccine.  The patient's medical history was not reported. Concomitant medications were not provided by the reporter.  On an unspecified date, prior to the onset of events, the patient received the first unplanned dose of mRNA-1273 (lot number: unknown) via Intramuscular route for the prophylaxis of COVID-19 infection.  No treatment medication was reported.  Action taken with mRNA-1273 in response to the event was unknown.  The outcome of the event was resolved at the time of this report.; Reporter's Comments: This report refers to a case of product administered to patient of inappropriate age (16 year old) for mRNA-1273 (lot number unknown) with no associated AEs reported.
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: Itchy rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (Itchy rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included RAMIPRIL (ALTACE), ESOMEPRAZOLE SODIUM (NEXIUM [ESOMEPRAZOLE SODIUM]) and CLOPIDOGREL BISULFATE (PLAVIX) for an unknown indication.   On 02-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced RASH PRURITIC (Itchy rash). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form and HYDROCORTISONE at a dose of 1 dosage form. At the time of the report, RASH PRURITIC (Itchy rash) had not resolved. Not Provided          concomitant medications include OTC supplements. Treatment details included Benadryl, Hydrocortisone topical. Action taken with mRNA-1273 in response to the drug was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 08-May-2021: Patient still have a rash despite dermatologist treatment , urgent care visit and visit to primary care physician.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Dosing error (pediatric use); A spontaneous report was received from a healthcare professional concerning a 17 year old patient who received first dose of Moderna's COVID-19 Vaccine (mRNA-1273) and experienced Product administered to patient of inappropriate age.  The patient's medical history, was not provided. Concomitant product use was not provided by the reporter.    On an unknown date, the patient received the first of two planned doses of mRNA-1273 (Batch number: 023M20A) intramuscularly  for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the event Product administered to patient of inappropriate age.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was unknown.   The outcome of the event, Product administered to  patient of inappropriate age, was considered resolved.; Sender's Comments: This report refers to a case of Product Administered to Patient of Inappropriate Age for mRNA-1273 (Lot number: 023M20A) with no associated AEs.
Age: 68.0
Sex: U
Vaccine: COVID19
Symptoms: Diarrhoea, Headache, Nausea, Vomiting
Clinical narrative: vomiting; severe headache; nausea; diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea) in a 68-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.    On 18-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea). At the time of the report, VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea) had not resolved.            No relevant Concomitant medications were reported.   No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 19-Mar-2021 and was forwarded to Moderna on 19-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea) in a 68-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.    On 18-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea). At the time of the report, VOMITING (vomiting), HEADACHE (severe headache), NAUSEA (nausea) and DIARRHOEA (diarrhea) had not resolved.            No relevant Concomitant medications were reported.   No Treatment information for the event was provided.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dyspnoea, Fatigue, Feeling hot, Headache
Clinical narrative: warm; scratchy throat; stuffy nose; thick mucus; tired; muscle pain; headaches; chills; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus) and FATIGUE (tired) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022M20A and 032L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Seasonal allergy. Concomitant products included NAPROXEN for Back pain and Back pain, ENALAPRIL for Blood pressure.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus), FATIGUE (tired), MYALGIA (muscle pain), HEADACHE (headaches) and CHILLS (chills). At the time of the report, FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus), FATIGUE (tired), MYALGIA (muscle pain), HEADACHE (headaches) and CHILLS (chills) outcome was unknown.            Patient has received Tylenol treatment for the symptoms.  Action taken with mRNA-1273 in response to the event was not applicable.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Increased viscosity of upper respiratory secretion, Myalgia, Oropharyngeal discomfort
Clinical narrative: warm; scratchy throat; stuffy nose; thick mucus; tired; muscle pain; headaches; chills; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus) and FATIGUE (tired) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022M20A and 032L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Seasonal allergy. Concomitant products included NAPROXEN for Back pain and Back pain, ENALAPRIL for Blood pressure.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus), FATIGUE (tired), MYALGIA (muscle pain), HEADACHE (headaches) and CHILLS (chills). At the time of the report, FEELING HOT (warm), OROPHARYNGEAL DISCOMFORT (scratchy throat), DYSPNOEA (stuffy nose), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (thick mucus), FATIGUE (tired), MYALGIA (muscle pain), HEADACHE (headaches) and CHILLS (chills) outcome was unknown.            Patient has received Tylenol treatment for the symptoms.  Action taken with mRNA-1273 in response to the event was not applicable.
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: Pregnant patient received both doses of vaccine; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant patient received both doses of vaccine) in a female patient of an unknown age (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 22-Feb-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant patient received both doses of vaccine). On 19-Mar-2021, EXPOSURE DURING PREGNANCY (Pregnant patient received both doses of vaccine) had resolved. Not Provided          Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Fatigue, Headache, Myalgia
Clinical narrative: chills; fever; fatigue; muscle pain; It's sort of having COVID again; sore arm - right arm; headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm - right arm), HEADACHE (headache), CHILLS (chills), PYREXIA (fever) and FATIGUE (fatigue) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in February 2021. Concurrent medical conditions included Arthritis rheumatoid.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm - right arm) and HEADACHE (headache). On 18-Mar-2021, the patient experienced CHILLS (chills), PYREXIA (fever), FATIGUE (fatigue), MYALGIA (muscle pain) and COVID-19 (It's sort of having COVID again). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 19-Mar-2021, HEADACHE (headache), CHILLS (chills), PYREXIA (fever), FATIGUE (fatigue), MYALGIA (muscle pain) and COVID-19 (It's sort of having COVID again) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm - right arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient used ibuprofen as treatment medication.  No concomitant medications were reported.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: chills; fever; fatigue; muscle pain; It's sort of having COVID again; sore arm - right arm; headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm - right arm), HEADACHE (headache), CHILLS (chills), PYREXIA (fever) and FATIGUE (fatigue) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in February 2021. Concurrent medical conditions included Arthritis rheumatoid.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm - right arm) and HEADACHE (headache). On 18-Mar-2021, the patient experienced CHILLS (chills), PYREXIA (fever), FATIGUE (fatigue), MYALGIA (muscle pain) and COVID-19 (It's sort of having COVID again). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 19-Mar-2021, HEADACHE (headache), CHILLS (chills), PYREXIA (fever), FATIGUE (fatigue), MYALGIA (muscle pain) and COVID-19 (It's sort of having COVID again) had resolved. At the time of the report, PAIN IN EXTREMITY (sore arm - right arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient used ibuprofen as treatment medication.  No concomitant medications were reported.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Feeling hot, Headache, Nasopharyngitis, Pain in extremity
Clinical narrative: Freezing; Arm felt hot; Vomiting; Severe Headache; slight temperature; Chills; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting) and HEADACHE (Severe Headache) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 023M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 17-Feb-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). On 18-Mar-2021, the patient experienced NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting), HEADACHE (Severe Headache), PYREXIA (slight temperature) and CHILLS (Chills). At the time of the report, PAIN IN EXTREMITY (Sore arm), NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting), HEADACHE (Severe Headache), PYREXIA (slight temperature) and CHILLS (Chills) outcome was unknown. Not Provided          No concomitant medications reported.  Treatment medications was not provided by the reporter  Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-051543 (Patient Link).
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Freezing; Arm felt hot; Vomiting; Severe Headache; slight temperature; Chills; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting) and HEADACHE (Severe Headache) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 023M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 17-Feb-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). On 18-Mar-2021, the patient experienced NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting), HEADACHE (Severe Headache), PYREXIA (slight temperature) and CHILLS (Chills). At the time of the report, PAIN IN EXTREMITY (Sore arm), NASOPHARYNGITIS (Freezing), FEELING HOT (Arm felt hot), VOMITING (Vomiting), HEADACHE (Severe Headache), PYREXIA (slight temperature) and CHILLS (Chills) outcome was unknown. Not Provided          No concomitant medications reported.  Treatment medications was not provided by the reporter  Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-051543 (Patient Link).
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Headache, Pyrexia
Clinical narrative: Loss of taste; Headache; Fever; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Loss of taste), HEADACHE (Headache) and PYREXIA (Fever) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced AGEUSIA (Loss of taste), HEADACHE (Headache) and PYREXIA (Fever). At the time of the report, AGEUSIA (Loss of taste), HEADACHE (Headache) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Incomplete course of vaccination, Vaccination site pain, Vaccination site pruritus, Vaccination site rash
Clinical narrative: severe rash on the left arm; Painful arm; itchy; did not want to receive the second dose; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE RASH (severe rash on the left arm), VACCINATION SITE PAIN (Painful arm), VACCINATION SITE PRURITUS (itchy) and INCOMPLETE COURSE OF VACCINATION (did not want to receive the second dose) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Mar-2021, the patient experienced INCOMPLETE COURSE OF VACCINATION (did not want to receive the second dose). On 19-Mar-2021, the patient experienced VACCINATION SITE RASH (severe rash on the left arm), VACCINATION SITE PAIN (Painful arm) and VACCINATION SITE PRURITUS (itchy). At the time of the report, VACCINATION SITE RASH (severe rash on the left arm), VACCINATION SITE PAIN (Painful arm) and VACCINATION SITE PRURITUS (itchy) outcome was unknown and INCOMPLETE COURSE OF VACCINATION (did not want to receive the second dose) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was included. Patient was treated with steroids.
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea
Clinical narrative: Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (Diarrhea). At the time of the report, DIARRHOEA (Diarrhea) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by reporter. Treatment medication not reported.    Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Nausea
Clinical narrative: chills; nausea; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills), NAUSEA (nausea) and FATIGUE (tiredness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced CHILLS (chills), NAUSEA (nausea) and FATIGUE (tiredness). On 10-Mar-2021, CHILLS (chills), NAUSEA (nausea) and FATIGUE (tiredness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Injection site pain, Overdose
Clinical narrative: Second dose on more than 28 days; Pain and soreness at injection site; Received 1ml of Moderna Covid vaccine as 1st dose; This spontaneous case was reported by a nurse and describes the occurrence of OVERDOSE (Received 1ml of Moderna Covid vaccine as 1st dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose on more than 28 days) and INJECTION SITE PAIN (Pain and soreness at injection site) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 044A21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (compazine  ), Drug allergy (vancomycin ) and Drug allergy (doxycycline).   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 ml. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Jan-2021, the patient experienced OVERDOSE (Received 1ml of Moderna Covid vaccine as 1st dose) and INJECTION SITE PAIN (Pain and soreness at injection site). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose on more than 28 days). The patient was treated with IBUPROFEN ongoing since an unknown date for Symptomatic treatment, at an unspecified dose and frequency. On 26-Jan-2021, OVERDOSE (Received 1ml of Moderna Covid vaccine as 1st dose) had resolved. On 29-Jan-2021, INJECTION SITE PAIN (Pain and soreness at injection site) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose on more than 28 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness
Clinical narrative: dizziness; weakness.; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness) and ASTHENIA (weakness.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (dizziness) and ASTHENIA (weakness.). At the time of the report, DIZZINESS (dizziness) and ASTHENIA (weakness.) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 30-Mar-2021: Patient demographics, outcome of events updated On 11-May-2021: No new information
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Dysgeusia, Heart rate increased, Nausea, Ocular discomfort
Clinical narrative: itchiness redness and hardness in the injection site; itchiness redness and hardness in the injection site; itchiness redness and hardness in the injection site; metallic/chemical taste in mouth; heart beat real fast; visual changes; lightheaded; the veins in both hands were quite large, bulging; super nauseated; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded) and VASODILATATION (the veins in both hands were quite large, bulging) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Anaphylaxis (Anaphylaxis to Ibuprofen, penicillin, aspirin).    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded), VASODILATATION (the veins in both hands were quite large, bulging) and NAUSEA (super nauseated). On 18-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness redness and hardness in the injection site), VACCINATION SITE ERYTHEMA (itchiness redness and hardness in the injection site) and VACCINATION SITE INDURATION (itchiness redness and hardness in the injection site). At the time of the report, DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded), VASODILATATION (the veins in both hands were quite large, bulging), NAUSEA (super nauseated), VACCINATION SITE PRURITUS (itchiness redness and hardness in the injection site), VACCINATION SITE ERYTHEMA (itchiness redness and hardness in the injection site) and VACCINATION SITE INDURATION (itchiness redness and hardness in the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications provided. No treatment medications were reported. Patient was pre-medicated with antihistamine.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site induration, Vaccination site pruritus, Vasodilatation
Clinical narrative: itchiness redness and hardness in the injection site; itchiness redness and hardness in the injection site; itchiness redness and hardness in the injection site; metallic/chemical taste in mouth; heart beat real fast; visual changes; lightheaded; the veins in both hands were quite large, bulging; super nauseated; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded) and VASODILATATION (the veins in both hands were quite large, bulging) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Anaphylaxis (Anaphylaxis to Ibuprofen, penicillin, aspirin).    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded), VASODILATATION (the veins in both hands were quite large, bulging) and NAUSEA (super nauseated). On 18-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness redness and hardness in the injection site), VACCINATION SITE ERYTHEMA (itchiness redness and hardness in the injection site) and VACCINATION SITE INDURATION (itchiness redness and hardness in the injection site). At the time of the report, DYSGEUSIA (metallic/chemical taste in mouth), HEART RATE INCREASED (heart beat real fast), OCULAR DISCOMFORT (visual changes), DIZZINESS (lightheaded), VASODILATATION (the veins in both hands were quite large, bulging), NAUSEA (super nauseated), VACCINATION SITE PRURITUS (itchiness redness and hardness in the injection site), VACCINATION SITE ERYTHEMA (itchiness redness and hardness in the injection site) and VACCINATION SITE INDURATION (itchiness redness and hardness in the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications provided. No treatment medications were reported. Patient was pre-medicated with antihistamine.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Injection site pain, Injection site pruritus, Pain
Clinical narrative: Injection site redness (deep redness); Injection site tenderness; injection site itching; Body ache; headache; Injection site tenderness; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body ache), HEADACHE (headache), the first episode of INJECTION SITE PAIN (Injection site tenderness), FATIGUE (fatigue) and VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PAIN (Body ache), HEADACHE (headache), the first episode of INJECTION SITE PAIN (Injection site tenderness) and FATIGUE (fatigue). On 19-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)), the second episode of INJECTION SITE PAIN (Injection site tenderness) and INJECTION SITE PRURITUS (injection site itching). At the time of the report, PAIN (Body ache), HEADACHE (headache), FATIGUE (fatigue), VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)), the last episode of INJECTION SITE PAIN (Injection site tenderness) and INJECTION SITE PRURITUS (injection site itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided. Lab details were not provided.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema
Clinical narrative: Injection site redness (deep redness); Injection site tenderness; injection site itching; Body ache; headache; Injection site tenderness; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body ache), HEADACHE (headache), the first episode of INJECTION SITE PAIN (Injection site tenderness), FATIGUE (fatigue) and VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PAIN (Body ache), HEADACHE (headache), the first episode of INJECTION SITE PAIN (Injection site tenderness) and FATIGUE (fatigue). On 19-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)), the second episode of INJECTION SITE PAIN (Injection site tenderness) and INJECTION SITE PRURITUS (injection site itching). At the time of the report, PAIN (Body ache), HEADACHE (headache), FATIGUE (fatigue), VACCINATION SITE ERYTHEMA (Injection site redness (deep redness)), the last episode of INJECTION SITE PAIN (Injection site tenderness) and INJECTION SITE PRURITUS (injection site itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided. Lab details were not provided.
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Pulmonary arterial hypertension. Concomitant products included TREPROSTINIL SODIUM (REMODULIN) from 02-Feb-2021 to an unknown date for an unknown indication.    On 26-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced DIZZINESS (Dizziness). At the time of the report, DIZZINESS (Dizziness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Joint range of motion decreased, Limb discomfort, Musculoskeletal stiffness
Clinical narrative: Arm hurts more; less range of motion; elbow feels tight; stiffness in left shoulder and arm; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 19-Mar-2021 and was forwarded to Moderna on 19-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (stiffness in left shoulder and arm), LIMB DISCOMFORT (Arm hurts more), JOINT RANGE OF MOTION DECREASED (less range of motion) and ARTHRALGIA (elbow feels tight) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     No reported medical history.     On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, the patient experienced MUSCULOSKELETAL STIFFNESS (stiffness in left shoulder and arm). On 19-Mar-2021, the patient experienced LIMB DISCOMFORT (Arm hurts more), JOINT RANGE OF MOTION DECREASED (less range of motion) and ARTHRALGIA (elbow feels tight). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) at a dose of 1 dosage form. At the time of the report, MUSCULOSKELETAL STIFFNESS (stiffness in left shoulder and arm), LIMB DISCOMFORT (Arm hurts more), JOINT RANGE OF MOTION DECREASED (less range of motion) and ARTHRALGIA (elbow feels tight) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Follow-up information received on 18-May-2021 contains non-significant information.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity, Somnolence
Clinical narrative: feel Sleepy; Feeling tired; Soreness of Right arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness of Right arm), SOMNOLENCE (feel Sleepy) and FATIGUE (Feeling tired) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Diabetes. Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) and VITAMINS NOS for an unknown indication.    On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, the patient experienced PAIN IN EXTREMITY (Soreness of Right arm). On 16-Mar-2021, the patient experienced SOMNOLENCE (feel Sleepy) and FATIGUE (Feeling tired). At the time of the report, PAIN IN EXTREMITY (Soreness of Right arm), SOMNOLENCE (feel Sleepy) and FATIGUE (Feeling tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Additional concomitant medications included unspecified medicines for blood pressure and diabetes.  Patient did not take any treatment for the symptoms.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Follow up received: No new information.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Headache, Nausea, Pyrexia
Clinical narrative: This spontaneous case was reported by a nurse and describes the occurrence of ASTHENIA (Loss of Energy), HEADACHE (Headache), NAUSEA (NAUSEA), CHILLS (Chills) and PYREXIA (Low grade fever) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L28) for COVID-19 vaccination.     The patient's past medical history included no adverse drug effect.   On 03-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced ASTHENIA (Loss of Energy), HEADACHE (Headache), NAUSEA (NAUSEA), CHILLS (Chills) and PYREXIA (Low grade fever). In February 2021, ASTHENIA (Loss of Energy), HEADACHE (Headache), NAUSEA (NAUSEA), CHILLS (Chills) and PYREXIA (Low grade fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   There is no concomitants drugs information was provided. No treatment information provided.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Oral herpes, Pain, Pyrexia
Clinical narrative: cold sores flared up on lips; Nausea; Fever; Intense pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Intense pain), ORAL HERPES (cold sores flared up on lips), NAUSEA (Nausea) and PYREXIA (Fever) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, the patient experienced PAIN (Intense pain), NAUSEA (Nausea) and PYREXIA (Fever). On 21-Mar-2021, the patient experienced ORAL HERPES (cold sores flared up on lips). At the time of the report, PAIN (Intense pain), ORAL HERPES (cold sores flared up on lips), NAUSEA (Nausea) and PYREXIA (Fever) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.   Treatment information was not provided.   Reporter did not allow further contact
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Pfizer Dose One) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No relevant medical history reported).    On 09-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jan-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Pfizer Dose One). On 01-Jan-2021, INTERCHANGE OF VACCINE PRODUCTS (Pfizer Dose One) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Reporter did not allow further contact
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Lymphadenopathy, Magnetic resonance imaging, Mammogram, Paraesthesia
Clinical narrative: Abnormal Lymph Nodes under right arm; Tingling sensation in both feet; Numbness in all toes; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Abnormal Lymph Nodes under right arm), PARAESTHESIA (Tingling sensation in both feet) and HYPOAESTHESIA (Numbness in all toes) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Mar-2021 at 11:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, the patient experienced PARAESTHESIA (Tingling sensation in both feet) and HYPOAESTHESIA (Numbness in all toes). On 16-Mar-2021 at 2:15 PM, the patient experienced LYMPHADENOPATHY (Abnormal Lymph Nodes under right arm). At the time of the report, LYMPHADENOPATHY (Abnormal Lymph Nodes under right arm), PARAESTHESIA (Tingling sensation in both feet) and HYPOAESTHESIA (Numbness in all toes) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Mar-2021, Magnetic resonance imaging: abnormal (abnormal) abnormal lymph nodes under my right arm. On 16-Mar-2021, Mammogram: abnormal (abnormal) abnormality.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medication was reported. The treatment information was unknown.   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Follow-up information was received on 18-May-2021 contains information regarding the reporter, the patient's demographics, and the outcome of the events.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Pain, Pain in extremity
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm for a couple of days no other reaction it wasn't extremely sore nor unbearable), PAIN (has a degenerative joint disease and has pain in her neck and right shoulder), ARTHRALGIA (bad pain on her knee which has arthritis), FATIGUE (tiredness and fatigue) and FATIGUE (tired) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination. Concurrent medical conditions included Degenerative joint disease and Seizure. On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced PAIN (has a degenerative joint disease and has pain in her neck and right shoulder), ARTHRALGIA (bad pain on her knee which has arthritis) and FATIGUE (tiredness and fatigue). On 18-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm for a couple of days no other reaction it wasn't extremely sore nor unbearable). On an unknown date, the patient experienced FATIGUE (tired). At the time of the report, PAIN IN EXTREMITY (sore arm for a couple of days no other reaction it wasn't extremely sore nor unbearable), PAIN (has a degenerative joint disease and has pain in her neck and right shoulder), ARTHRALGIA (bad pain on her knee which has arthritis), FATIGUE (tiredness and fatigue) and FATIGUE (tired) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. No relevant concomitant medications were reported. No treatment information was provided. Most recent FOLLOW-UP information incorporated above includes: On 09-May-2021: Events were resolved and consumer consented to follow up via phone.